Please assess the completion status of the following clinical trial:

Trial Title: Trial of Panitumumab/Cisplatin/Fluorouracil Combined With Radiation in Esophageal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Locally Advanced Esophageal cancer (stages T1N1 or T2-4 any N)~2. Histology must be adenocarcinoma or squamous cell carcinoma~3. Must be surgical candidate based on evaluation by a thoracic surgeon~4. must have adequate organ function as defined by routine lab tests~Exclusion Criteria:~1. Insitu carcinoma~2. prior chemotherapy for esophageal cancer~3. Metastatic (stage IV disease)~4. Tumors \<5cm from the cricopharyngeus muscle, Tumors with \>75% of tumor located within the stomach~5. Active, uncontrolled cardiac disease~6. subjects with \>Grade 2 neuropathies. -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Level -1 (Type: EXPERIMENTAL): Panitumumab/Cisplatin/Fluorouracil and Radiation therapy 1.5mg/kg Panitumumab, 60mg/m2 cisplatin, 750mg/m2 5FU (Fluorouracil)
- Dose Level 1 (Type: EXPERIMENTAL): Panitumumab/Cisplatin/Fluorouracil and Radiation therapy 1.5mg/kg Panitumumab, 80mg/m2 cisplatin, 1000mg/m2 5FU (Fluorouracil)

Based on this trial design, predict the completion outcome and termination type (if applicable).